GOZZETTI ALESSANDRO

Alessandro
Gozzetti
Professore Associato

Contacts

0577586784 [int.0577586784]

Curriculum Vitae

Teaching activities

Completion accademic year: 2026/2027

Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2024/2025
Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2024/2025
Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2024/2025
Course year: 4 Full cicle (6 years) MEDICINA E CHIRURGIA A.Y. 2023/2024

Completion accademic year: 2025/2026

Course year: 1 First cycle degree (DM 270) CARDIOCIRCULATORY AND CARDIOVASCULAR PERFUSION TECHNIQUES A.Y. 2025/2026
Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2023/2024
Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2023/2024
Course year: 4 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2022/2023

Completion accademic year: 2024/2025

Course year: 1 First cycle degree (DM 270) CARDIOCIRCULATORY AND CARDIOVASCULAR PERFUSION TECHNIQUES A.Y. 2024/2025
Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2022/2023

Research

Ultime pubblicazioni:

  • Tatangelo, V., Carullo, G., Lopresti, L., Ulivieri, C., Brogi, S., Butini, S., et al. (2026). Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4. APOPTOSIS, 31(7) [10.1007/s10495-026-02393-0]. - view more
  • Del Prete, R., Tusha, V., Simon-Molas, H., Gazziero, V.A., Nardi, F., Drago, R., et al. (2026). IL21—STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia. HEMASPHERE, 10(1) [10.1002/hem3.70292]. - view more
  • Frustaci, A.M., Galitzia, A., Lucignano, M., Appio, L., Olivieri, J., Sanna, A., et al. (2026). Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice. HAEMATOLOGICA, 111(1), 206-218 [10.3324/haematol.2025.287799]. - view more
  • Gay, F., Buda, G., Petrucci, M.T., Bolli, N., Cea, M., Derudas, D., et al. (2026). Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. ESMO OPEN, 11(3) [10.1016/j.esmoop.2025.106054]. - view more
  • Kumar, S., Jagannath, S., Weisel, K.C., Rosiñol, L., Leleu, X., Dimopoulos, M., et al. (2026). Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma. BLOOD CANCER JOURNAL, 16(1) [10.1038/s41408-026-01466-2]. - view more